Travere Therapeutics, Inc.
TVTX
$33.99
-$1.20-3.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 435.83M | 333.87M | 273.53M | 233.18M | 203.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 435.83M | 333.87M | 273.53M | 233.18M | 203.45M |
| Cost of Revenue | 220.55M | 220.38M | 225.88M | 225.24M | 224.93M |
| Gross Profit | 215.28M | 113.49M | 47.65M | 7.94M | -21.48M |
| SG&A Expenses | 305.01M | 284.17M | 272.73M | 264.12M | 258.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 525.55M | 504.55M | 498.62M | 489.36M | 483.14M |
| Operating Income | -89.73M | -170.68M | -225.09M | -256.18M | -279.69M |
| Income Before Tax | -88.55M | -169.10M | -225.93M | -320.51M | -348.70M |
| Income Tax Expenses | -5.00K | -97.00K | -32.00K | 120.00K | 260.00K |
| Earnings from Continuing Operations | -88.54 | -169.00 | -225.90 | -320.63 | -348.96 |
| Earnings from Discontinued Operations | 4.00K | -55.00K | -812.00K | -915.00K | -2.50M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.54M | -169.06M | -226.71M | -321.55M | -351.45M |
| EBIT | -89.73M | -170.68M | -225.09M | -256.18M | -279.69M |
| EBITDA | -35.03M | -120.54M | -178.61M | -212.63M | -238.74M |
| EPS Basic | -1.05 | -2.04 | -2.81 | -4.10 | -4.56 |
| Normalized Basic EPS | -0.64 | -1.26 | -1.73 | -2.01 | -2.20 |
| EPS Diluted | -1.06 | -2.04 | -2.81 | -4.10 | -4.56 |
| Normalized Diluted EPS | -0.67 | -1.26 | -1.73 | -2.01 | -2.20 |
| Average Basic Shares Outstanding | 349.64M | 338.19M | 326.74M | 315.52M | 308.89M |
| Average Diluted Shares Outstanding | 363.03M | 338.19M | 326.74M | 315.52M | 308.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |